Thymalfasin: clinical pharmacology and antiviral applications.
Gramenzi. A A; Cursaro. C C; Andreone. P P; Bernardi. M M
Key Findings
- Boosts Th1‑type T‑cell responses important for antiviral defense
- Shows potential as a single‑agent therapy for chronic hepatitis B
- May improve outcomes when combined with interferon‑alpha for hepatitis B and C
Practical Outcomes
- The peptide isn’t ready for DIY use as a general health booster; its main promise is for specific viral liver diseases. Until larger trials define safe doses and schedules, biohackers should treat it as experimental and seek medical supervision if considering it for immune support.
Summary
Thymosin‑alpha1 (Thymalfasin) is a peptide that can boost certain immune cells, especially the ones that fight viruses. Early studies suggest it might help treat chronic hepatitis B on its own and work better with interferon‑alpha for both hepatitis B and C, but bigger trials are still needed.
Abstract
Thymalfasin (thymosin-alpha1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-alpha for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.
Study Information
pubmed
1998
2020-02-02T00:00:00.000Z
10.2165/00063030-199809060-00005